Alliance Focuses on Novel, Small Molecule Therapeutics Targeting Epigenetic Enzymes for the Treatment of Cancer and Other Diseases CAMBRIDGE, Mass., Oct. 3, 2012 /PRNewswire-USNewswire/ -- Epizyme, Inc ., a company leading the discovery and development of personalized therapeutics for patients with genetically defined cancers, announced today $4 million in milestone payments from collaborator GlaxoSmithKline (GSK) based on the achievement of pre-clinical milestones. In 2011, Epizyme and GSK formed a worldwide strategic alliance to discover, develop, and market novel small molecule therapeutics targeting histone methyltransferases (HMTs), an important class of epigenetic enzymes, for the treatment of cancer and other diseases. These milestone payments follow $4 million in milestone payments from GSK to Epizyme in October 2011, bringing the total milestone payments to Epizyme to $8 million to date.